BioWorld MedTech
Archive Search

User ID

Password

Forgot password

Remember my login



New User ?

BioWorld MedTech Twitter

Clarivate Analytics

Today's Issue of BioWorld MedTech

Monday, November 20, 2017

Today's Headlines

Startup preps launch for first FDA-cleared device to treat opioid withdrawal symptoms

In this age of the opioid epidemic, drug overdose has become the leading cause of death in the U.S. for people under 50 years of age. Payers and providers are desperate to reverse the swelling tide. Now, the FDA has cleared the first device for use in helping to reduce the symptoms of opioid withdrawal.

Disruption and change on tap for med-tech industry, says panel on future of leadership

SAN JOSE, Calif. – Panelists tackled data, innovation and changes organizations need to make to adapt to the upcoming trends in a session at the Advance Medical Technology Association's (AdvaMed) MedTech Conference. An all-female panel of speakers discussed what leadership should do to prepare for business movement toward big data and machine learning, consumer trends and valuing people in an organization at "The future of leadership in medtech: trends of disruption and consolidation" panel.

Genetics of depression yielding secrets, but diagnostic use a ways off

Looking at the prevalence data on depression is enough to set off depression in itself. According to the Clarivate Analytics Incidence & Prevalence Database (IPD), the global prevalence of depression is a bit under 5 percent. Because depression is not a permanent condition, however, a person's lifetime risk of an episode of major depression is 15 percent. The adolescent depression rate is even higher. Antidepressants are one effective way to treat depression. But they are not effective for everyone.


Home   |   About Us   |   Contact Us   |   Copyright Notices   |   Terms of Use   |   Privacy Statement

clarivate.com | BioWorld.com | bioworldmedtech.com